FDA approves Biogen Alzheimer’s drug for first time in 18 years

Biogen to seek FDA approval for Alzheimer's drug Aducanumab

VistaGen Therapeutics Inc (VTGN) Hakkında

Anxiety-Focused Stock Vistagen Therapeutics Is An Undervalued Late-Stage Neurology Player: Analyst - Vistagen Therapeutics (NASDAQ:VTGN)

Biogen has been an 'uninvestable' stock for awhile, says Mizuho's Jared Holz

Biogen shares soar following promising Alzheimer's drug findings

Investors should have known better to blame Biogen for Alzheimer's drug failure, says WSJ reporter